Clinical and translational allergy
Long-Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry
By Veldhuis N, Achten RE, van Luijk CM and 10 others.
Abstract
Background
Dupilumab-associated ocular surface disease (DAOSD) is the most reported side effect in dupilumab-treated atopic dermatitis (AD) patients. We investigated the effect of long-term dupilumab treatment on ocular surface disease (OSD), conjunctival goblet cells (GCs), and tear fluid dupilumab levels and proteins.